Skip to main content
OpenTrials

Clinical trial condition

Haemophilus Infections

Explore clinical trials studying Haemophilus Infections. Study availability and eligibility vary by location and protocol.

158 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Haemophilus Infections trial results

Completed

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

NCT01978093

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Fayetteville, Arkansas, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
  • GSK Investigational Site Fresno, California, United States
View all 26 locations
View Trial Details
Completed

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

NCT00129116

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Asse, Belgium
  • GSK Investigational Site Drongen, Belgium
  • GSK Investigational Site Ghent, Belgium
  • GSK Investigational Site Maldegem, Belgium
View all 26 locations
View Trial Details
Completed

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

NCT00586612

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Barcelona, Spain
  • GSK Investigational Site Bilbao, Spain
  • GSK Investigational Site Burgos, Spain
  • GSK Investigational Site Getafe, Spain
View Trial Details
Completed

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

NCT00326118

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Garran, Australian Capital Territory, Australia
  • GSK Investigational Site Randwick, New South Wales, Australia
  • GSK Investigational Site Westmead, New South Wales, Australia
  • GSK Investigational Site Herston, Queensland, Australia
View Trial Details
Completed

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

NCT00129129

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Fountain Valley, California, United States
  • GSK Investigational Site Centennial, Colorado, United States
  • GSK Investigational Site Norwich, Connecticut, United States
View all 27 locations
View Trial Details
Completed

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

NCT00289783

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Bryant, Arkansas, United States
View all 93 locations
View Trial Details
Completed

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

NCT01248884

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +32 more
Locations
  • GSK Investigational Site Santo Domingo, Dominican Republic
  • GSK Investigational Site Santo Domingo, Distrito Nacional, Dominican Republic
  • GSK Investigational Site Espoo, Finland
  • GSK Investigational Site Helsinki, Finland
View all 16 locations
View Trial Details

Related conditions